Last updated: September 15, 2026
Fevipiprant, also known as QAW039, is an oral, selective prostaglandin D2 receptor 2, or CRTh2, antagonist developed by Novartis for severe eosinophilic asthma and related inflammatory diseases. Its clinical program ended after two pivotal Phase III asthma trials failed to show a statistically significant reduction in moderate-to-severe exacerbations. Fevipiprant has no FDA approval, no commercial launch, no Orange Book listing, and no established biosimilar or generic market.
The commercial projection is therefore effectively zero for the base case. Any future value would require a new sponsor, a new indication, or a materially different biomarker-defined development strategy.
What is fevipiprant and how does it work?
Fevipiprant is an orally administered small-molecule antagonist of the prostaglandin D2 receptor 2, also called CRTh2 or GPR44. The receptor is expressed on eosinophils, basophils and type 2 helper T cells. Prostaglandin D2 signaling contributes to recruitment and activation of these inflammatory cells in asthma.
The development thesis was that daily oral CRTh2 blockade could reduce eosinophilic inflammation without the administration burden and cost of injectable biologic therapies. Fevipiprant was intended primarily for patients with severe asthma who remained uncontrolled despite high-dose inhaled corticosteroids and additional controller therapy.
| Attribute |
Fevipiprant |
| Development code |
QAW039 |
| Mechanism |
Selective CRTh2 / DP2 receptor antagonist |
| Modality |
Oral small molecule |
| Lead developer |
Novartis |
| Primary target disease |
Severe eosinophilic asthma |
| Other investigated areas |
Eosinophilic airway inflammation and related type 2 inflammatory conditions |
| Regulatory status |
Not approved |
| FDA approval |
None |
| Commercial status |
No launch |
| Biosimilar exposure |
None |
| Generic exposure |
No marketed generic |
Novartis acquired rights to fevipiprant through its collaboration with Argenta, which had discovered and developed CRTh2 antagonists. Public development materials identified QAW039 as a Novartis respiratory pipeline asset before the program was discontinued.
What happened in the fevipiprant Phase III trials?
The pivotal asthma program consisted principally of the LUSTER-1 and LUSTER-2 trials. Both trials evaluated fevipiprant in patients with uncontrolled asthma at risk of exacerbations despite standard controller therapy.
| Trial |
ClinicalTrials.gov identifier |
Disease area |
Development stage |
Outcome |
| LUSTER-1 |
NCT02555683 |
Severe asthma |
Phase III |
Primary endpoint not met |
| LUSTER-2 |
NCT02563067 |
Severe asthma |
Phase III |
Primary endpoint not met |
| Earlier dose-ranging studies |
Multiple identifiers |
Asthma with eosinophilic inflammation |
Phase II |
Biological activity observed, but no validated clinical benefit sufficient for approval |
The primary objective was to determine whether fevipiprant reduced the annualized rate of moderate-to-severe asthma exacerbations compared with placebo. Novartis reported that neither Phase III study met its primary endpoint. The company subsequently ended development in asthma. (Novartis, 2019; ClinicalTrials.gov, n.d.-a; ClinicalTrials.gov, n.d.-b)
The result was commercially important because the program had advanced beyond proof-of-concept and into a large, controlled Phase III package. Earlier studies had suggested reductions in airway eosinophils and other inflammatory markers, but those pharmacodynamic effects did not translate into a sufficient reduction in clinical exacerbations.
When did fevipiprant lose development momentum?
Fevipiprant’s development status changed materially between 2018 and 2020.
| Period |
Development event |
| 2015-2016 |
Phase III LUSTER studies initiated |
| 2017-2018 |
Phase II and mechanistic studies continued to evaluate eosinophilic inflammation and asthma control |
| 2019 |
Novartis reported that LUSTER-1 and LUSTER-2 failed their primary endpoints |
| 2019-2020 |
The asthma development program was discontinued |
| 2021-2024 |
No public evidence of regulatory filing, commercial launch, or resumed pivotal development |
Novartis’ subsequent pipeline disclosures no longer treated fevipiprant as a commercial respiratory growth asset. No FDA New Drug Application, European marketing authorization application, or approval decision has been publicly associated with the compound.
What is the FDA regulatory status of fevipiprant?
Fevipiprant has no FDA approval and no U.S. regulatory exclusivity period.
| FDA category |
Status |
| Approved drug |
No |
| New Drug Application |
No public approval record |
| Orphan-drug approval |
None identified |
| Fast Track approval |
None identified |
| Breakthrough Therapy designation |
None identified |
| Qualified infectious disease product |
Not applicable |
| Pediatric exclusivity |
None |
| Reference-listed drug |
None |
Because fevipiprant was never approved, it does not have an FDA commercial exclusivity period. The compound therefore has no conventional Hatch-Waxman launch date and no U.S. generic approval pathway tied to an approved reference product.
What is the Orange Book status of fevipiprant?
Fevipiprant has no Orange Book listing. The absence of an approved reference product prevents an ANDA applicant from using fevipiprant as a conventional FDA reference-listed drug.
The following consequences apply:
- There is no Orange Book patent listing for an approved fevipiprant product.
- There is no Paragraph IV certification against a listed patent.
- There is no 30-month stay linked to a Paragraph IV notice.
- There is no statutory generic launch date under the Hatch-Waxman framework.
- Any future approval would require a new sponsor to establish safety, efficacy, chemistry, manufacturing and controls, unless a regulatory pathway recognized prior clinical data.
Are there Paragraph IV challenges or patent litigation involving fevipiprant?
No public Paragraph IV challenge, ANDA litigation case, or commercial patent dispute involving an approved fevipiprant product has been established.
The absence of Paragraph IV litigation reflects the compound’s development failure and lack of approval. Patent disputes may still arise around abandoned clinical candidates, research use, or future redevelopment, but those issues are different from an Orange Book-listed product challenge.
Publicly accessible records do not establish an active commercial dispute comparable to the litigation surrounding approved asthma drugs such as Advair, Nucala, Fasenra, Dupixent or Tezspire.
What patents protect fevipiprant?
Fevipiprant was protected during development by compound, composition, formulation and therapeutic-use patent families associated with CRTh2 antagonists. Argenta and later Novartis were the principal commercial parties associated with the program.
A precise current patent-by-patent freedom-to-operate conclusion cannot be inferred from the clinical history alone. Patent families may include:
- Genus patents covering substituted heterocyclic CRTh2 antagonists.
- Species patents directed to fevipiprant or closely related compounds.
- Salt, polymorph and pharmaceutical-composition claims.
- Oral dosage-form claims.
- Methods of treating asthma or eosinophilic inflammation.
- Manufacturing and intermediate claims.
The practical value of these rights has declined because the compound did not reach approval. Patent term is measured from the relevant earliest nonprovisional or international filing dates, subject to jurisdiction-specific adjustments. Any unexpired claims would protect particular chemical structures, formulations or uses, but they would not create FDA exclusivity without an approved product.
How strong is the fevipiprant patent estate?
The estate appears commercially weak relative to an approved respiratory product for three reasons:
- The lead indication failed in Phase III.
- No approved product creates an enforceable Orange Book linkage.
- A future sponsor would face clinical redevelopment risk regardless of remaining patent life.
The estate could retain defensive value if a company develops another CRTh2 antagonist or seeks to revive fevipiprant in a biomarker-selected population. That value is likely lower than the value of a patent estate supporting an approved biologic with long-term claims covering composition, dosing and manufacturing.
What formulations are protected by fevipiprant patents?
Fevipiprant was developed as an oral small molecule, with clinical studies using once-daily or twice-daily oral dosing regimens depending on the trial design and dose cohort. The potential formulation scope includes tablets, active pharmaceutical ingredient compositions, salts and crystalline forms.
No commercial formulation reached the market. As a result:
- There is no approved extended-release product.
- There is no inhaled fevipiprant product.
- There is no depot injection.
- There is no marketed combination product.
- There is no recognized formulation-based regulatory barrier to generic competition.
Any surviving formulation claims would have value only if a sponsor re-established the compound’s clinical and commercial relevance.
What method-of-use patents cover fevipiprant?
The principal method-of-use concept was treatment of asthma and eosinophilic airway inflammation through CRTh2 antagonism. Potential claims may distinguish:
- Severe asthma.
- Eosinophilic asthma.
- Patients with elevated blood or sputum eosinophils.
- Prevention of asthma exacerbations.
- Combination treatment with inhaled corticosteroids or long-acting bronchodilators.
- Treatment of nasal or airway inflammation.
Method-of-use claims face a substantial practical limitation. The pivotal trials failed to demonstrate the intended exacerbation benefit across the studied populations. A future sponsor would need a narrower, evidence-based population to support a new use patent or regulatory filing.
How does fevipiprant compare with competing asthma therapies?
Fevipiprant competed against both established inhaled therapy and injectable biologics.
| Therapy class |
Representative products |
Administration |
Commercial position |
| Inhaled corticosteroid and bronchodilator combinations |
Advair, Symbicort, Breo Ellipta |
Inhaled |
Standard controller therapy |
| Anti-IgE biologic |
Xolair |
Injection |
Established severe allergic asthma product |
| Anti-IL-5 / IL-5R biologics |
Nucala, Fasenra |
Injection |
Established eosinophilic asthma products |
| Anti-IL-4R biologic |
Dupixent |
Injection |
Broad type 2 inflammatory disease franchise |
| Anti-TSLP biologic |
Tezspire |
Injection |
Severe asthma product with broad biomarker positioning |
| CRTh2 antagonist |
Fevipiprant |
Oral |
Discontinued development |
Fevipiprant’s proposed advantages were oral dosing, a potentially broad anti-inflammatory effect and direct suppression of eosinophil trafficking. Its disadvantages were the failure to reduce exacerbations in Phase III and the loss of commercial timing as biologic competitors expanded.
What is the biosimilar and generic risk for fevipiprant?
There is no current biosimilar risk because fevipiprant is a small molecule, not a biologic. The relevant issue would be generic or follow-on small-molecule competition if the drug were approved.
A future generic entry scenario would depend on:
- Re-establishment of an approved reference product.
- Surviving compound or formulation patents.
- Any new regulatory exclusivity.
- Commercial demand after relaunch.
- Whether a new sponsor developed the same molecule or a salt, polymorph or formulation variant.
If fevipiprant were approved after redevelopment, composition-of-matter patents would be the most important barrier. Formulation and method-of-use patents would provide narrower protection and could be bypassed through alternative dosing, formulation or labeling strategies, subject to applicable regulatory law.
Which companies are challenging or developing fevipiprant?
No company is publicly identified as conducting an active late-stage fevipiprant program through the latest broadly available public disclosures.
The competitive CRTh2 field has included other investigational agents, such as:
- Setipiprant, also known as QAW039’s broader class competitor in early development, associated with Actelion and later other development efforts.
- OC000459, an oral CRTh2 antagonist developed by Oxagen.
- Timapiprant and other DP2 receptor antagonists investigated by multiple companies.
Most CRTh2 programs encountered the same central issue: reductions in inflammatory biomarkers did not consistently produce clinically meaningful improvements in asthma outcomes. This diminished the attractiveness of the mechanism compared with validated biologic targets.
What licensing deals affect fevipiprant?
Fevipiprant originated from Argenta’s CRTh2 research program and was developed commercially by Novartis under a collaboration or licensing arrangement. Novartis became the principal development and commercialization party.
No later transaction establishing a new global owner, regional licensee or commercialization partner has been broadly disclosed after the asthma program was discontinued. The lack of a visible asset transfer reduces the probability of near-term redevelopment.
Any future transaction would likely be structured as an asset acquisition, option agreement or regional license rather than a conventional launch partnership because the principal clinical indication has already failed.
What is the market projection for fevipiprant?
The base-case market projection is zero through the near term because fevipiprant has no active pivotal program, no approval and no commercial supply chain.
| Scenario |
Probability profile |
Market implication |
| Base case: no redevelopment |
Highest |
No revenue and no launch |
| Indication repositioning in eosinophilic disease |
Low |
Requires new Phase II evidence and differentiated biomarker strategy |
| Relaunch in a narrow asthma subgroup |
Low |
Potential niche product, but faces biologic competition |
| Licensing to a new sponsor |
Low |
Could create option value, not near-term sales |
| Generic or follow-on entry |
Not applicable currently |
Requires prior approval and an approved reference product |
A successful redevelopment would face a high commercial bar. The product would need to show a clinically meaningful benefit over biologics, inhaled standard therapy or emerging oral anti-inflammatory agents. Oral convenience alone would probably be insufficient because severe asthma specialists already have multiple targeted biologics with established outcomes data.
What revenue exposure does fevipiprant create for Novartis?
Fevipiprant does not create current product revenue exposure for Novartis. It is not included in the company’s marketed respiratory portfolio and has no reported commercial sales base.
The financial exposure is primarily sunk development expenditure and foregone option value. The failed Phase III program also reduced the potential value of Novartis’ CRTh2 research platform. It does not create material current revenue-at-risk comparable to an approved blockbuster facing loss of exclusivity.
Key Takeaways
- Fevipiprant is an oral CRTh2 antagonist developed by Novartis for severe eosinophilic asthma.
- The LUSTER-1 and LUSTER-2 Phase III studies failed their primary exacerbation endpoints.
- Novartis discontinued the asthma development program.
- Fevipiprant has no FDA approval, Orange Book listing, commercial exclusivity or marketed product.
- No Paragraph IV litigation, generic launch case or biosimilar competition has been identified.
- Patent value is primarily defensive and depends on the scope and survival of compound, formulation and method-of-use claims.
- The base-case commercial forecast is zero.
- Redevelopment would require a new sponsor, a differentiated biomarker-selected population and new clinical evidence.
- Biologic competition from Nucala, Fasenra, Dupixent and Tezspire makes a broad asthma relaunch commercially unattractive.
FAQs About Fevipiprant
Is fevipiprant still being developed?
No active late-stage development program has been publicly established. Novartis discontinued the asthma program after the LUSTER Phase III trials failed.
Can fevipiprant still be approved in the future?
A future sponsor could seek approval after generating new clinical evidence, but prior Phase III failure would make a conventional relaunch unlikely without a narrower indication or new patient-selection strategy.
Is fevipiprant a biologic?
No. Fevipiprant is an orally administered small molecule. It would face generic competition rather than biosimilar competition if it ever reached approval.
Does fevipiprant have an expiration date?
No single commercial patent expiration date controls the molecule because it was never approved and may be covered by multiple patent families. The relevant dates depend on the specific compound, formulation and use claims in each jurisdiction.
What caused fevipiprant’s commercial failure?
The main cause was failure to reduce moderate-to-severe asthma exacerbations in pivotal Phase III trials. Biomarker and eosinophil effects were not sufficient to establish a clinically meaningful benefit against placebo and competing targeted therapies.
References
-
ClinicalTrials.gov. (n.d.-a). Study of QAW039 in patients with uncontrolled asthma despite use of inhaled corticosteroid plus long-acting beta2 agonist: LUSTER-1. U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT02555683
-
ClinicalTrials.gov. (n.d.-b). Study of QAW039 in patients with uncontrolled asthma despite use of inhaled corticosteroid plus long-acting beta2 agonist: LUSTER-2. U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT02563067
-
Novartis. (2019). Novartis reports topline results from Phase III LUSTER studies of fevipiprant in uncontrolled asthma. Novartis corporate communications.
-
Novartis. (2020). Annual report 2019. Novartis AG.
-
Brightling, C. E., et al. (2019). Efficacy and safety of fevipiprant in patients with severe asthma: Results from randomized clinical development studies. The Lancet Respiratory Medicine.